Logo

FDA Issues an Alert on Medtronic's Pacemaker or Cardiac Resynchronization Therapy Pacemaker for its Premature Battery Depletion

Share this

FDA Issues an Alert on Medtronic's Pacemaker or Cardiac Resynchronization Therapy Pacemaker for its Premature Battery Depletion

Shots:

  • FDA issues an alert to inform patients and health care practitioners about the unexpected drainage of Medtronic’s implantable pacemakers leading to a serious injury or death. The affected CRT-P includes Azure- Astra- Percepta- Serena and Solara models
  • The alert is due to three events where device’s capacitor cracked- without any warning to the patient or health care provider. As of April 10- 2019- 131-889 have been sold in the US and doctors were unable to communicate with the device due to battery depletion resulting in loss of pacemaker function leading to dizziness- death- within a year of pacemaker implantation
  • Medtronic's MyCareLink Monitor helps patients to monitor battery status and general functioning of their implanted pacemaker or CRT-P. the device is designed with ~7.5 and 15 years or 6 and 10 years before requiring battery replacement. The US FDA approves enhancement in the device to detect capacitor failures in new devices- reducing the risk of premature battery depletion

- Ref: FDA | Image: Medtronics

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions